Exagen Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Public

  • Employees
  • 179

Employees

  • Stock Symbol
  • XGN

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $1.96
  • (As of Friday Closing)

Exagen General Information

Description

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Contact Information

Website
www.exagen.com
Formerly Known As
Exagen Diagnostics
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Laboratory Services (Healthcare)
Other Industries
Biotechnology
Stock Exchange
NAS
Corporate Office
  • 1261 Liberty Way
  • Vista, CA 92081
  • United States
+1 (888) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Exagen Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.96 $1.98 $1.30 - $3.32 $34.1M 17.4M 48.5K -$1.09

Exagen Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 14,633 30,228 4,976 109,098
Revenue 55,733 52,548 45,563 48,299
EBITDA (16,717) (20,669) (44,494) (23,119)
Net Income (19,361) (23,689) (47,387) (26,851)
Total Assets 50,808 56,944 86,221 123,445
Total Debt 23,477 23,721 35,201 28,065
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Exagen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Exagen‘s full profile, request access.

Request a free trial

Exagen Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Exagen‘s full profile, request access.

Request a free trial

Exagen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis a
Laboratory Services (Healthcare)
Vista, CA
179 As of 2023
00000
000000000 00000

000000

bore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation
0000000000 00000000
Sunnyvale, CA
00 As of 0000
000.00
000000 0 000.00

000000

ipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua
0000000000000
Louisville, CO
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Exagen Competitors (20)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
CellMax Life Venture Capital-Backed Sunnyvale, CA 00 000.00 000000 0 000.00
Biodesix Formerly VC-backed Louisville, CO 000 00000 000000000 00000
Biocept Formerly VC-backed San Diego, CA 00 00000 000000000000 00000
Advanced Cell Diagnostics Formerly VC-backed Minneapolis, MN 000 000.00 000000&0 000.00
ARUP Laboratories Corporation Salt Lake City, UT 0000 0000000000
You’re viewing 5 of 20 competitors. Get the full list »

Exagen Patents

Exagen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220299510-A1 Methods for diagnosing, prognosing and monitoring treatment for thrombosis in subjects with systemic lupus erythematosus Pending 12-Aug-2019 0000000000
US-20210220389-A1 Methods for diagnosing, prognosing and monitoring treatment for thrombosis in subjects with systemic lupus erythematosus Inactive 12-Aug-2019 00000000000
CA-3150479-A1 Methods for diagnosing, prognosing and monitoring treatment for thrombosis in subjects with systemic lupus erythematosus Pending 12-Aug-2019 00000000000
EP-4013296-A1 Methods for diagnosing, prognosing and monitoring treatment for thrombosis in subjects with systemic lupus erythematosus Pending 12-Aug-2019 0000000000
EP-4013296-A4 Methods for diagnosing, prognosing and monitoring treatment for thrombosis in subjects with systemic lupus erythematosus Pending 12-Aug-2019 G01N33/6893 0
To view Exagen’s complete patent history, request access »

Exagen Executive Team (26)

Name Title Board Seat Contact Info
Jonathan Aballi Chief Executive Officer, President & Board Member
Kamal Adawi Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Ming-Chou Lee Chief Technology Officer
Tom Macpherson Region Sales Director
Andrew Concoff MD Chief Innovation Officer
You’re viewing 5 of 26 executive team members. Get the full list »

Exagen Board Members (18)

Name Representing Role Since
Ana Hooker Exagen Board Member 000 0000
Bruce Robertson Ph.D H.I.G. BioHealth Partners Board Member 000 0000
Ebetuel Pallares Ph.D Cottonwood Technology Fund Board Member 000 0000
Paul Kim Ph.D Self Board Member 000 0000
Tina Nova Ph.D Tullis Health Investors Chairman & Board Member 000 0000
You’re viewing 5 of 18 board members. Get the full list »

Exagen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Exagen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Exagen‘s full profile, request access.

Request a free trial

Exagen Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cypress Bioscience (Diagnostic Business) 08-Oct-2010 0000000000 000 Biotechnology
To view Exagen’s complete acquisitions history, request access »

Exagen ESG

Risk Overview

Risk Rating

Updated April, 01, 2022

23.52 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 14,912

Rank

00.00

Percentile

Healthcare

Industry

00 of 616

Rank

00.0

Percentile

Medical Services

Subindustry

00 of 114

Rank

00.00

Percentile

To view Exagen’s complete esg history, request access »

Exagen FAQs

  • When was Exagen founded?

    Exagen was founded in 2002.

  • Who is the founder of Exagen?

    Cole Harris and Waneta Tuttle Ph.D are the founders of Exagen.

  • Who is the CEO of Exagen?

    Jonathan Aballi is the CEO of Exagen.

  • Where is Exagen headquartered?

    Exagen is headquartered in Vista, CA.

  • What is the size of Exagen?

    Exagen has 179 total employees.

  • What industry is Exagen in?

    Exagen’s primary industry is Laboratory Services (Healthcare).

  • Is Exagen a private or public company?

    Exagen is a Public company.

  • What is Exagen’s stock symbol?

    The ticker symbol for Exagen is XGN.

  • What is the current stock price of Exagen?

    As of 14-Jun-2024 the stock price of Exagen is $1.96.

  • What is the current market cap of Exagen?

    The current market capitalization of Exagen is $34.1M.

  • What is Exagen’s current revenue?

    The trailing twelve month revenue for Exagen is $55.7M.

  • Who are Exagen’s competitors?

    CellMax Life, Biodesix, Biocept, Advanced Cell Diagnostics, and ARUP Laboratories are some of the 20 competitors of Exagen.

  • What is Exagen’s annual earnings per share (EPS)?

    Exagen’s EPS for 12 months was -$1.09.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »